NK Cell Therapies Pipeline Report 2024: Insights on 80+ Companies and 100+ Pipeline Drugs, Including ALECSAT (CytoVac), NKTR-214/Bempegaldesleukin (Nektar Therapeutics), and Monalizumab (Innate Pharma) [Yahoo! Finance]
Natural Killer (NK) Cell Therapy Pipeline Research Report 2024: Comprehensive Insights About 100+ Companies and 185+ Pipeline Drugs [Yahoo! Finance]
Sezary Syndrome Pipeline Insights 2024, Featuring Major Players 4SC, Seagen, Merck Sharp & Dohme, Innate Pharma, Trillium Therapeutics and Secura Bio [Yahoo! Finance]
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024 [Yahoo! Finance]
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024